MarketPulse

Special Protocol Assessment

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Secures FDA Approval for Optic Neuritis Trial Design, Clearing Path to Drug Submission

Oculis secures FDA agreement on Phase 3 trial design for Privosegtor optic neuritis treatment, de-risking regulatory pathway and clearing way for future drug submission.
OCSOCSAWFDA approvalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Clears FDA Hurdle for Optic Neuritis Drug in $7B Market

Oculis secures FDA Special Protocol Assessment for Privosegtor Phase 3 trial, de-risking path to potential $7 billion optic neuritis market.
OCSOCSAWFDA approvalPhase 3 trial